Advertisement

Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer’s Disease

  • Stephen M. Day
  • Tao MaEmail author
Insight

Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the most common form of dementia in the elderly. Concurrent with an aging population, the incidence of AD has been rising steadily and become a global threat to public health [1]. Unfortunately, there are currently no effective interventions that can cure AD or slow its progression, and recently finished clinical trials targeting brain amyloid-β (Aβ) accumulation have not succeeded in improving cognitive impairments in AD patients [1]. Thus, it is necessary and urgent to identify alternative disease-modifying strategies to alleviate AD pathophysiology. In this perspective article, we focus on glucagon-like peptide-1 (GLP-1), specifically its natural cleavage product GLP-1 (9-36), as a potential therapeutic approach for AD.

Biology of GLP-1

GLP-1 is an incretin hormone released from the L-cells of the distal ileum in response to nutrient ingestion. This proglucagon protein is a prohormone which gives rise to several...

Notes

Acknowledgements

This insight was supported by the National Institutes of Health, USA (K99/R00 AG044469, R01 AG055581, and R01 AG056622), and the BrightFocus Foundation (A2017457S).

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med 2011, 3: 77sr71.Google Scholar
  2. 2.
    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132: 2131–2157.CrossRefPubMedGoogle Scholar
  3. 3.
    Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001, 142: 521–527.CrossRefPubMedGoogle Scholar
  4. 4.
    Andersen A, Lund A, Knop FK, Vilsboll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018, 14: 390–403.CrossRefPubMedGoogle Scholar
  5. 5.
    Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang H-Y, Ahima RS, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 2018, 14: 168–181.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Najem D, Bamji-Mirza M, Yang Z, Zhang W. Aβ-induced insulin resistance and the effects of insulin on the cholesterol synthesis pathway and Aβ secretion in neural cells. Neurosci Bull 2016, 32: 227–238.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Holscher C. Drugs developed for treatment of diabetes show protective effects in Alzheimer’s and Parkinson’s diseases. Acta Physiol Sin 2014, 66: 497–510.Google Scholar
  8. 8.
    During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9: 1173–1179.CrossRefPubMedGoogle Scholar
  9. 9.
    Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer’s disease. Behav Brain Res 2009, 205: 265–271.CrossRefPubMedGoogle Scholar
  10. 10.
    Li T, Jiao JJ, Holscher C, Wu MN, Zhang J, Tong JQ, et al. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3×Tg mouse model of Alzheimer’s disease. Hippocampus 2018, 28: 358–372.CrossRefPubMedGoogle Scholar
  11. 11.
    Perry TL, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003, 72: 603–612.CrossRefPubMedGoogle Scholar
  12. 12.
    Gault VA, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008, 587: 112–117.CrossRefPubMedGoogle Scholar
  13. 13.
    McClean PL, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci 2011, 31: 6587–6594.CrossRefPubMedGoogle Scholar
  14. 14.
    Ma T, Klann E. Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer’s disease. J Neurochem 2012, 120 Suppl 1: 140–148.CrossRefPubMedGoogle Scholar
  15. 15.
    Giacco F, Du X, Carratú A, Gerfen GJ, D’Apolito M, Giardino I, et al. GLP-1 Cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop. Diabetes 2015, 64: 3273–3284.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E. Glucagon-like peptide-1 cleavage product GLP-1 (9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer’s Disease Model Mice. J Neurosci 2012, 32: 13701–13708.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007, 53: 703–717.CrossRefPubMedGoogle Scholar
  18. 18.
    Ma T, Tzavaras N, Tsokas P, Landau EM, Blitzer RD. Synaptic stimulation of mTOR is mediated by Wnt signaling and regulation of glycogen synthetase kinase-3. J Neurosci 2011, 31: 17537–17546.CrossRefPubMedGoogle Scholar
  19. 19.
    Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J Neurochem 2008, 104: 1433–1439.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ma T. GSK3 in Alzheimer’s disease: mind the isoforms. J Alzheimers Dis 2014, 39: 707–710.CrossRefPubMedGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, Gerontology and Geriatric MedicineWake Forest School of MedicineWinston-SalemUSA
  2. 2.Department of Physiology and PharmacologyWake Forest School of MedicineWinston-SalemUSA
  3. 3.Department of Neurobiology and AnatomyWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations